Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    PDSC01 - Product Showcase

    • Type: Product Showcases
    • Track: N.A.
    • +

      PDSC01.01 - 360° Perspectives on Biomarker Testing in Non-Small Cell Lung Cancer by PFIZER

      00:00 - 00:00

      • Abstract

      Abstract not provided

    • +

      PDSC01.02 - Clinical Perspectives on the use of VIZIMPRO® (dacomitinib) as a First-line Treatment for Adults with Advanced or Metastatic NSCLC with EGFR-activating Mutations by PFIZER

      00:00 - 00:00

      • Abstract

      Abstract not provided

    • +

      PDSC01.03 - A 15 Min Catch Up on New Developments in NGS for Oncologists by THERMO FISHER SCIENTIFIC

      00:00 - 00:00

      • Abstract

      Abstract not provided

  • +

    JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC

    • Type: Workshop
    • Track: N.A.
    • +

      JICC01.01 - Chair

      07:00 - 07:00  |  Presenter: Yi-long Wu

      • Abstract

      Abstract not provided

    • +

      JICC01.02 - Chair

      07:00 - 07:00  |  Presenter: Tony S. Mok

      • Abstract

      Abstract not provided

    • +

      JICC01.03 - Chair

      07:00 - 07:00  |  Presenter: Chunxue Bai

      • Abstract

      Abstract not provided

    • +

      JICC01.04 - Chair

      07:00 - 07:00  |  Presenter: Caicun Zhou

      • Abstract

      Abstract not provided

    • +

      JICC01.05 - Single-Cell Sequencing Atlas of Tumor-associated Microvascular Endothelial Cell in Lung Cancer

      07:00 - 07:15  |  Presenter: Dawei Yang

      • Abstract

      Abstract not provided

    • +

      JICC01.06 - From Antibody to Small Molecule: What is the Difference?

      07:15 - 07:30  |  Presenter: Heather Wakelee

      • Abstract

      Abstract not provided

    • +

      JICC01.07 - Oral VEGFR Inhibitor Monotherapy for Lung Cancer: Should We or Should We Not?

      07:30 - 07:45  |  Presenter: Robert Pirker

      • Abstract

      Loading...

    • +

      JICC01.08 - Target Driver Gene and Target VEGFR: Could Prolong OS?

      07:45 - 08:00  |  Presenter: Ying Cheng

      • Abstract

      Abstract not provided

    • +

      JICC01.09 - Small Molecule Anti-VEGFR Combination with PD-1/PD-L1 Blockades: New Hope?

      08:00 - 08:15  |  Presenter: Shengxiang Ren

      • Abstract

      Abstract not provided

    • +

      JICC01.10 - Live Panel Discussion

      08:15 - 08:25

      • Abstract

      Abstract not provided

    • +

      JICC01.11 - Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study

      08:25 - 08:30  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      JICC01.12 - Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Chinese Advanced Non-Small Cell Lung Cancer

      08:30 - 08:35  |  Presenter: Xiaomin Niu

      • Abstract

      Loading...

    • +

      JICC01.13 - Discussant

      08:35 - 08:40  |  Presenter: Si-Yang Liu

      • Abstract

      Abstract not provided

    • +

      JICC01.14 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy

      08:40 - 08:45  |  Presenter: Qing Zhou

      • Abstract

      Loading...

    • +

      JICC01.15 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study

      08:45 - 08:50  |  Presenter: Yan Wang

      • Abstract

      Loading...

    • +

      JICC01.16 - Discussant: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC

      08:50 - 08:55  |  Presenter: Xiaorong Dong

      • Abstract

      Abstract not provided

    • +

      JICC01.17 - Live Panel Discussion

      08:55 - 09:00

      • Abstract

      Abstract not provided

  • +

    IS01 - Satellite CME Symposium by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer

    • Type: Satellite CME Symposia
    • Track:
    • +

      IS01.01 - Welcome, Introduction and Baseline Assessment

      09:15 - 09:20

      • Abstract

      Abstract not provided

    • +

      IS01.02 - Introduction to Novel Antibody–Drug Conjugates for Treatment of NSCLC

      09:20 - 09:30

      • Abstract

      Abstract not provided

    • +

      IS01.03 - Presentation on Activity of ADCS in Clinical Trials for Lung Cancer

      09:30 - 09:40

      • Abstract

      Abstract not provided

    • +

      IS01.04 - Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC

      09:40 - 09:55

      • Abstract

      Abstract not provided

    • +

      IS01.05 - Panel Discussion and Q&A

      09:55 - 10:10

      • Abstract

      Abstract not provided

    • +

      IS01.06 - Summary, Final Thoughts, Post Education Assessment and Q&A

      10:10 - 10:15

      • Abstract

      Abstract not provided

  • +

    IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC

    • Type: Industry Symposium
    • Track:
    • +

      IS02.01 - Opening Remarks

      10:30 - 10:35  |  Presenter: Masahiro Tsuboi

      • Abstract

      Abstract not provided

    • +

      IS02.02 - Current Strategies for IO Therapy for Unresectable Stage III NSCLC

      10:35 - 10:45  |  Presenter: Glenwood Dillon Goss

      • Abstract

      Abstract not provided

    • +

      IS02.03 - Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC

      10:45 - 10:55  |  Presenter: Suresh Senan

      • Abstract

      Abstract not provided

    • +

      IS02.04 - Defining the Role of Immunotherapy in the Treatment of ES-SCLC

      10:55 - 11:05  |  Presenter: Myung-Ju Ahn

      • Abstract

      Abstract not provided

    • +

      IS02.05 - Emerging Biomarkers in SCLC

      11:05 - 11:15  |  Presenter: Charles M. Rudin

      • Abstract

      Abstract not provided

    • +

      IS02.06 - Panel Discussion / Q&A Panel Discussion

      11:15 - 11:30

      • Abstract

      Abstract not provided

  • +

    IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges

    • Type: Industry Symposium
    • Track:
    • +

      IS03.01 - Welcome and Introduction

      11:45 - 11:50  |  Presenter: Tony S. Mok

      • Abstract

      Abstract not provided

    • +

      IS03.02 - Evolving Challenges for the Treatment of Advanced NSCLC

      11:50 - 12:00  |  Presenter: Tony S. Mok

      • Abstract

      Abstract not provided

    • +

      IS03.03 - Emerging ADC Targets for the Treatment of Late-Line NSCLC

      12:00 - 12:15  |  Presenter: Pasi Antero Jänne

      • Abstract

      Abstract not provided

    • +

      IS03.04 - ADC Therapies as Targeted Treatment Options in Patients With Advanced NSCLC

      12:15 - 12:30  |  Presenter: James Chih-Hsin Yang

      • Abstract

      Abstract not provided

    • +

      IS03.05 - Interactive Q&A/Panel Discussion

      12:30 - 12:45

      • Abstract

      Abstract not provided

  • +

    IS04 - Industry Symposium Sponsored by Lilly Oncology: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices

    • Type: Industry Symposium
    • Track:
    • +

      IS04.01 - Chair’s Welcome

      13:00 - 13:04  |  Presenter: Koichi Goto

      • Abstract

      Abstract not provided

    • +

      IS04.02 - Introduction to the Topic - A Brief Overview of the 15-Year Journey of Biomarker Driven Management of NSCLC

      13:04 - 13:10  |  Presenter: Koichi Goto

      • Abstract

      Abstract not provided

    • +

      IS04.03 - Developing Best Practices for the Accurate Diagnosis and Treatment of All Patients With NSCLC - Practical Tips on Optimising Diagnostic Capabilities in the Clinic

      13:10 - 13:22  |  Presenter: Herbert H Loong

      • Abstract

      Abstract not provided

    • +

      IS04.04 - The Roles of the Oncologist and Pathologist in Providing an Actionable Diagnosis - Discuss the Role of the Tumour Board / MDT in Implementing Precision Medicine

      13:22 - 13:34  |  Presenter: Fernando Lopez-Rios

      • Abstract

      Abstract not provided

    • +

      IS04.05 - Gaining Consensus - An Overview of the IASLC, NCCN and ESMO Guidelines for Treating and Testing Patients

      13:34 - 13:44  |  Presenter: Giuseppe Curigliano

      • Abstract

      Abstract not provided

    • +

      IS04.06 - Panel Discussion and Q&A

      13:44 - 14:00

      • Abstract

      Abstract not provided

    • +

      IS04.07 - Symposium Close

      14:00 - 14:00  |  Presenter: Koichi Goto

      • Abstract

      Abstract not provided

  • +

    IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer

    • Type: Industry Symposium
    • Track:
    • +

      IS05.01 - Welcome and Introductions

      14:15 - 14:15  |  Presenter: Rina Hui

      • Abstract

      Abstract not provided

    • +

      IS05.02 - Frontline Immunotherapy Treatment Options in mNSCLC

      14:15 - 14:30  |  Presenter: Rina Hui

      • Abstract

      Abstract not provided

    • +

      IS05.03 - Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer

      14:30 - 14:45  |  Presenter: Roy S. Herbst

      • Abstract

      Abstract not provided

    • +

      IS05.04 - Choosing Immunotherapy Alone or in Combination in 1L MNSCLC

      14:45 - 15:00  |  Presenter: Corey J. Langer

      • Abstract

      Abstract not provided

    • +

      IS05.05 - Q&A and Closing Remarks

      15:00 - 15:15  |  Presenter: Rina Hui, Roy S. Herbst, Corey J. Langer

      • Abstract

      Abstract not provided

  • +

    IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC

    • Type: Industry Symposium
    • Track:
    • +

      IS06.01 - Welcome and Introduction

      15:30 - 15:30  |  Presenter: Yi-long Wu

      • Abstract

      Abstract not provided

    • +

      IS06.02 - Evolution of the NSCLC Treatment Landscape

      15:30 - 15:40  |  Presenter: Yi-long Wu

      • Abstract

      Abstract not provided

    • +

      IS06.03 - Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?

      15:40 - 15:55  |  Presenter: Johan Vansteenkiste

      • Abstract

      Abstract not provided

    • +

      IS06.04 - Panel Discussion

      15:55 - 16:07

      • Abstract

      Abstract not provided

    • +

      IS06.05 - Rethinking Inflammation to Improve Outcomes in NSCLC: Il-1 as an Emerging Target

      16:07 - 16:21  |  Presenter: Yasushi Goto

      • Abstract

      Abstract not provided

    • +

      IS06.06 - Q&A

      16:21 - 16:29

      • Abstract

      Abstract not provided

    • +

      IS06.07 - Closing

      16:29 - 16:30  |  Presenter: Yi-long Wu

      • Abstract

      Abstract not provided

  • +

    IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer

    • Type: Industry Symposium
    • Track:
  • +

    PL01 - Opening Plenary Session (Japanese, Mandarin, Spanish Translation Available)

    • Type: Plenary
    • Track: N.A.
    • +

      PL01.01 - Chair

      18:00 - 18:05  |  Presenter: Yi-long Wu

      • Abstract

      Abstract not provided

    • +

      PL01.02 - Chair

      18:05 - 18:10  |  Presenter: Daniel SW Tan

      • Abstract

      Abstract not provided

    • +

      PL01.03 - Chair

      18:10 - 18:10  |  Presenter: Ross Soo

      • Abstract

      Abstract not provided

    • +

      PL01.09 - Chair

      18:10 - 18:10  |  Presenter: Tetsuya Mitsudomi

      • Abstract

      Abstract not provided

    • +

      PL01.07 - IASLC Distinguished Service and Lectureship Awards (Not for CME Credit)

      18:10 - 18:30

      • Abstract

      Abstract not provided

    • +

      PL01.04 - Lung Cancer in China

      18:30 - 18:50  |  Presenter: Wanqing Chen

      • Abstract

      Abstract not provided

    • +

      PL01.05 - The New WHO Classification of Lung Tumors

      18:50 - 19:10  |  Presenter: Ming Sound Tsao

      • Abstract

      Loading...

    • +

      PL01.06 - Molecular Epidemiology of Asian Lung Cancer

      19:10 - 19:30  |  Presenter: Takashi Kohno

      • Abstract

      Loading...

    • +

      PL01.08 - Live Q&A

      19:30 - 20:00

      • Abstract

      Abstract not provided